Notably, MSCs engineered to overexpress let-7a have been shown to alleviate PAH progression by inhibiting PASMC growth through the STAT3-BMPR2 signaling cascade, thereby supporting a promising therapeutic strategy for PAH patients (Cheng et al., 2017b). Here, BMPR2 is linked to pulmonary arterial hypertension.